Loading, Please Wait...
SALT LAKE CITY, May 07, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention, announces its wholly owned subsidiary Predictive Laboratories has reached an enrollment milestone of 200 participants in its ongoing Institutional Review Board (IRB)-approved study of spine and joint disease leading to chronic pain.
The primary objective of the IRB study is to conduct genetic research related to healthcare advancement in the diagnosis, treatment and prevention of conditions causing chronic pain. The first 200 participants have volunteered for the study by submitting their DNA samples to the Predictive Biorepository and by reporting detailed medical information through their healthcare providers.
“One in five American adults suffer with chronic pain and the use of opioids to address pain has led to an epidemic of addiction and overdose as sufferers attempt to find relief,” said Bradley Robinson, CEO of Predictive Technology Group. “Patients have embraced the opportunity to enroll in this research study and participate in the search for a better solution to chronic pain. The Predictive Biorepository’s genetic and analytic capabilities are expected to add to an already robust pipeline of genetic data that will assist in the ongoing discovery of diagnostic tests and therapeutic treatments for disease.”
“We are excited about achieving this initial milestone as we work to build a foundation for the advancement of medicine to solve real problems for real people,” said Rick W. Obray, M.D., Chairman of Predictive’s Clinical Advisory Board. “Establishing these genetic building blocks is truly how the promise of personalized medicine will move toward reality.”
Predictive Laboratories, Inc. is the sponsor of the study. Kenneth Ward, MD, Laboratory Director of Predictive Laboratories, serves as Principal Investigator.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, called ARTGuide®, to selected Beta launch centers. ARTGuide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns, in 2018. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
For more information, contact Investor Relations: